Compared with bariatric surgery, less invasive and reversible techniques to counteract obesity and type 2 diabetes (T2D) have been developed, including the EndoBarrier Gastrointestinal Liner [duodenal-jejunal bypass sleeve (DJBS)]. We conducted a systematic review and meta-analyses of eligible trials to evaluate the efficacy and safety of the DJBS. Five randomized controlled trials (RCTs; 235 subjects) and 10 observational studies (211 subjects) were included. The risk of bias was evaluated as high in all studies. The mean body mass index ranged from 30 to 49.2 kg/m(2) and 10-100% of the subjects had T2D. Meta-analysis showed that the DJBS was associated with significant mean differences in body weight and excess weight loss of -5.1 kg [95% confidence interval (CI) -7.3, -3.0; four trials; n = 151; I(2) = 37%] and 12.6% (95% CI 9.0, 16.2; four trials; n = 166; I(2) = 24%), respectively, compared with diet modification. The mean differences in glycated haemoglobin (-0.9%; 95% CI -1.8, 0.0) and fasting plasma glucose (-3.7 mM; 95% CI -8.2, 0.8) among subjects with T2D did not reach statistical significance. Adverse events consisted mainly of abdominal pain, nausea and vomiting. No deaths occurred. Future high-quality long-term RCTs are needed to further assess efficacy and safety.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/dom.12603 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and safety of duodenal-jejunal bypass liner for obesity and type 2 diabetes: A systematic review and meta-analysis.
Obes Rev
November 2024
Department of Metabolic and Bariatric Surgery, The First Affiliated Hospital of Jinan University, Guangzhou, China.
This study aimed to evaluate the efficacy and safety of duodenal-jejunal bypass liner (DJBL) for obesity and type 2 diabetes mellitus. A comprehensive search of electronic databases was conducted up to September 15, 2022. Thirty studies involving 1751 patients were included.
View Article and Find Full Text PDFRemovable Transduodenal Bypass: Development of a New Endoscopic Concept.
Visc Med
August 2023
Department of Interdisciplinary Endoscopy, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Introduction: Obesity and obesity-related disease such as diabetes mellitus type 2 are a permanently rising concern worldwide. Current effective therapeutic options mostly include medication and surgery, but there is a lack of effective treatment options between medication and surgery. Previously, devices such as EndoBarrier have been placed on the market.
View Article and Find Full Text PDFCOVID-19 infection in patients on long-term home parenteral nutrition for chronic intestinal failure.
Clin Nutr ESPEN
June 2023
Centre for Intestinal Failure, Department of Gastroenterology and Nutritional Support, Hôpital Beaujon, Clichy, France.
Article Synopsis
- The study aimed to assess the incidence and severity of COVID-19 among patients receiving home parenteral nutrition (HPN) for chronic intestinal failure over a year-long observation period from March 2020 to March 2021.
- Out of 4680 patients from 68 centers across 23 countries, the cumulative incidence of COVID-19 infection was 9.6%, with 55.1% of patients providing COVID-related data, revealing varying rates of infection severity.
- Results indicated a higher incidence and severity of infection among deceased patients, and significant proportions of the cohort were unvaccinated or had unknown vaccination statuses; 42.8% of deaths in infected individuals were attributed to COVID-19.
Endoscopic sleeve gastroplasty for treatment of class 1 and 2 obesity (MERIT): a prospective, multicentre, randomised trial.
Lancet
August 2022
Department of Surgery, The University of Texas Health Science Center, Houston, TX, USA.
Background: Endoscopic sleeve gastroplasty (ESG) is an endolumenal, organ-sparing therapy for obesity, with wide global adoption. We aimed to explore the efficacy and safety of ESG with lifestyle modifications compared with lifestyle modifications alone.
Methods: We conducted a randomised clinical trial at nine US centres, enrolling individuals aged 21-65 years with class 1 or class 2 obesity and who agreed to comply with lifelong dietary restrictions.
Is duodeno-jejunal bypass liner superior to pylorus preserving bariatric surgery in terms of complications and efficacy?
Langenbecks Arch Surg
August 2021
Department of Surgery, Somogy County Kaposi Mor Teaching Hospital, Kaposvár, Hungary.
Purpose: Based on recent scientific evidence, bariatric surgery is more effective in the management of morbid obesity and related comorbidities than conservative therapy. Pylorus preserving surgical procedures (PPBS) such as laparoscopic single-anastomosis duodeno-jejunal or duodeno-ileal bypass with sleeve gastrectomy are modified duodenal switch (DS) surgical techniques. The duodeno-jejunal bypass liner (DJBL) is a novel surgical method in the inventory of metabolism focused manual interventions that excludes duodeno-jejunal mucosa from digestion, mimicking DS procedures without the risk of surgical intervention.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!